Withings Acquires Impeto Medical to Strengthen and Grow Its Research and Developmentof Medical Technologies
Leader in the tracking of peripheral neuropathies, acquired by pioneers of connected health
Issy les Moulineaux January 11, 2022, Withings, the pioneer of the connected health movement,
has announced the acquisi on of Impeto Medical, a specialist in R&D, manufacturing anddistribu on of innova ve medical devices for physicians.
This announcement incorporates the ownership of Impeto’s SUDOSCAN® technology, a leader in
detec ng and tracking peripheral neuropathies. The procurement will strengthen the research anddevelopment of new technologies for future Withings health products and services.
Established in 2005, Impeto Medical set new standards in detec ng and tracking small ber
neuropathy - damage or dysfunc on of small nerves - leveraging its proprietary SUDOSCAN®
technology. The FDA cleared solu on measures the ability of the sweat glands to release chloride
ions in response to an electrical s mulus on the palms of the hands and soles of the feet. The
degenera on of small nerve bers reduces sweat gland innerva on and impairs sudomotor func on.
SUDOSCAN®e cacy has been evaluated in the assessment of small ber peripheral neuropathies inseveral diseases states, including diabetes, Chemotherapy-induced polyneuropathy, family amyloid
polyneuropathy, and Fabry disease compared to gold-standard reference tests such as Skin biopsy or
Quan ta ve Sudomotor Axon Re ex Test( QSART). Its solu on has been licensed and embedded intoof thousands of devices for pharmacies, medical o ces and hospitals worldwide.
“We are delighted to announce the acquisi on of Impeto Medical as we welcome its experience andtechnologies into the Withings por olio. The company and its team have been important partners to
us in the past. Now, as part of Withings, we have an exci ng opportunity to con nue to deploy
together their exper se and Sudoscan technology in the development of a variety of devices thathave the poten al for people to monitor and manage various disease states from the comfort of theirhome” said Mathieu Letombe, Withings CEO.
The rst Withings product to incorporate SUDOSCAN® technology will be Withings Body Scan
recently announced during CES 2022. Following FDA clearance, Body Scan will provide at homeanalysis of biomarkers associated with common health condi ons. With the ability to monitor
segmental body composi on, heart rate, and vascular age, it will further advance the smart scale
category. With measurements that will assess nerve ac vity and heart rhythm using a 6-lead ECG,
Body Scan goes beyond weight management to become an unprecedented in-home connected
health sta on that can help users take proac ve measures.
As part of the deal, Withings has acquired all Impeto technology IP and patent. Impeto Medical sta
has become a full part of Withings. Exis ng Impeto Medical customers will con nue to be provided
with full support.
-Ends-

ff

fi

ti

ti

ti

ti

fi

ti

ti

ti

ti

ti

ffi

ffi

ti

ti

ti

ti

ti

ti

ti

tf

flti

fi

ti

ti

ti

ti

tf

ti

ffi

ti

ti

ti

ti

ti

ti

fi

About Withings
Established in 2008, Withings, is a world leader in connected health technology. Its team ofengineers, data scien sts, and healthcare professionals have enthused everyday, elegant lifestyleobjects with medical and wellness capabili es to e ciently track health vitals. Its range of in-homedevices can monitor more than 20 health parameters and are used daily by millions of people
worldwide. Its por olio of devices includes connected scales, hybrid watches, smart thermometers,
blood pressure monitors, and sleep trackers to empower individuals to take back control of theirhealth and track medical and wellness data.